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A B S T R A C T
MicroRNAs (miR) are small non-coding RNAs involved in the immune response regulation. miR-155 has
been attributed a major pro-inﬂammatory role in the pathogenesis of multiple sclerosis and its animal
model experimental autoimmune encephalomyelitis (EAE). Here, a role of miR-155 in re-activation of
encephalitogenic CD4+ T cells was investigated. Dark Agouti rats were immunized with myelin basic
protein (MBP) emulsiﬁed in complete Freund’s adjuvant. CD4+ T cells were puriﬁed from draining lymph
node cells (DLNC) obtained in the inductive phase and from spinal cord immune cells (SCIC) isolated at
the peak of EAE. CD4+ T cells obtained from SCIC (i.e., in vivo re-activated cells) had markedly higher
expression of miR-155 in comparison to those puriﬁed from DLNC (not re-activated). Likewise, in vitro re-
activation of DLNC with MBP led to increase in miR-155 expression. Further, DLNC and DLNC CD4+ T cells
were transfected with an inhibitor of miR-155 during in vitro re-activation. As a result, expression of
important CD4+ T cell effector cytokines IFN-g and IL-17, but not of regulatory cytokines IL-10 and TGF-b,
was reduced. These results imply that miR-155 supports re-activation of encephalitogenic CD4+ T cells.
Our results contribute to a view that miR-155 might be a valuable target in multiple sclerosis therapy.
ã 2015 Elsevier Masson SAS. All rights reserved.
1. Introduction
Multiple sclerosis is a chronic, inﬂammatory, demyelinating
and neurodegenerative disease of the central nervous system
(CNS). Experimental autoimmune encephalomyelitis (EAE) is a
model of multiple sclerosis that has been intensively contributing
to our understanding of the auto-immune response in the
disease pathogenesis [1]. It is widely accepted that immune
reactivity against the CNS antigens starts at the periphery where
auto-reactive T helper (Th) cells, belonging to Th1 and/or
Th17 population are activated [2,3]. While it is well known that
these encephalitogenic CD4+ T lymphocytes are activated in lymph
nodes draining the site of immunization (DLN) in EAE, the site of
their initial activation in multiple sclerosis is still elusive.
Nevertheless, it is widely accepted that, both in multiple sclerosis
and in EAE, these cells migrate into the CNS where they have to be
re-activated by local antigen-presenting cells in order to initiate
inﬂammation and autoimmune attack upon the CNS tissue [2,3].
Importantly this reactivation has to be performed in the
interaction of encephalitogenic T cells and professional antigen-
presenting cells, as CD4+ T cells are dependent on recognizing their
cognate antigens in a complex with MHC class II [2]. The
phenomenon of re-activation is not yet completely understood,
yet it is considered as “an absolute requirement” for pathogenesis
of inﬂammatory diseases of the CNS [2,3].
MicroRNAs (miR) are small non-coding RNAs that are important
post-transcriptional regulators of gene expression. They play a
profound role in regulation of the immune response, while their
aberrant expression is involved in onset and progress of immune-
related disorders, including autoimmune diseases [4]. Accordingly,
a number of miR have been found up-regulated or down-regulated
in various immune cells in multiple sclerosis [5]. Among these,
miR-155 seems to be particularly important for multiple sclerosis
pathogenesis. This miR was found elevated in peripheral blood
mononuclear cells of multiple sclerosis patients and a haplotype
of three single nucleotide polymorphisms corresponding to
mir-155 processing was associated with the disease status[6].
Also, miR-155 expression was up-regulated in active brain lesions
in multiple sclerosis where it was associated with impaired
expression of CD47 in astrocytes and with consequent dysregu-
lation of macrophage inﬂammatory activity [7]. Moreover,
miR-155 was shown of major importance for inﬂammatory activity
of microglia [8]. Finally, it was demonstrated essential for
differentiation of Th1 and Th17 cells [9]. Concordantly, deﬁciency
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of miR-155 protected mice from EAE through inhibition of
dendritic and Th17 cells [10].
Here, expression of miR-155 in the process of re-activation of
encephalitogenic cells was investigated. Also, effects of miR-
155 inhibition on cytokine production in encephalitogenic T cells
were determined. miR-155 expression correlated with the re-
activation, while the inhibition of its activity reduced generation of
typical Th1 and Th17 cytokines, i.e., IFN-g and IL-17, respectively.
2. Materials and methods
2.1. Experimental animals, EAE induction and evaluation
Female Dark Agouti rats were used in this study. The rats were
maintained in the animal facility of the Institute for Biological
Research “Siniša Stankovic.” Animal manipulation and experimen-
tal procedures were approved by the local Ethics Committee
(Approval N03-10/13 and 03-04/15). Active EAE was induced by
immunization of rats with myelin basic protein (MBP 100 mg/rat,
puriﬁed from guinea pig brains, kind gift from Professor Alexander
Fluegel, University of Goettingen, Germany) emulsiﬁed with
complete Freund’s adjuvant (CFA, Difco, Detroit, MI). The rats
were injected intradermally with 100 mL of the emulsion. Clinical
signs of EAE were scored as follows: 0 = no clinical signs; 1 = ﬂaccid
tail; 2 = hind-limb paresis; 3 = hind-limb paralysis; 4 = moribund
state or death.
2.2. Isolation of cells and cell cultures
Lymph node cells (LNC) were obtained from popliteal, inguinal
and para-aortal lymph nodes of un-immunized rats. Draining
lymph node cells (DLNC) were isolated from popliteal lymph nodes
on day 7 after the immunization (inductive phase of disease).
Spinal cord immune cells (SCIC) were obtained at the peak of
disease (13–15 days post immunization, clinical sign 2–4). from
spinal cords of the rats perfused with sterile phosphate buffered
saline. Spinal cords were homogenized and SCIC were obtained
from 30%/70% Percoll (Sigma–Aldrich, St. Louis, MO) gradient. CD4+
T cells were puriﬁed from DLNC and SCIC using biotin conjugated
antibody speciﬁc for CD4 (eBioscience, San Diego, CA) and IMagSAv
particles plus (BD Biosciences, San Diego, CA). The cells were
grown in RPMI-1640 medium (PAA Laboratories, Pasching, Austria)
supplemented with 2% rat serum(RS) for antigen-speciﬁc response
or with 5% fetal calf serum (FCS, PAA laboratories) for other
cultivations. MBP (10 mg/ml), anti-CD3 antibody and anti-
CD28 antibody (both from BD Biosciences, 1 mg/ml, each),
antagomiR-155 and irrelevant oligonucleotide (Anti-mmu-miR-
155-5p and negative control, both from Qiagen, Venlo,
Netherlands) were used for in vitro treatments.
2.3. Transfection of DLNC and CD4+ T cells
For transfection of the cells with anti-mmu-miR-155-5p a
lipofectamine-based method was applied. Chemical transfection of
DLNCs, SCICs and CD4+ T cells was performed by instructions
provided by the manufacturer (Santa Cruz Biotechnology, Dallas,
TX). 0.6  106 cells were seeded in a 24-well plate in 1.4 ml of RPMI-
1640 medium without antibiotics and serum. The transfection
complexes were formed by mixing 6 ml of antagomiR-155 (20 mM)
or 6 ml of negative control (20 mM) with the same volume of the
lipofectamine transfection reagent (Santa Cruz Biotechnology,
Dallas, TX or Invitrogen, Carlsbad, CA) in 100 ml of RPMI-
1640 medium. After incubation for 15–20 min at room tempera-
ture, the transfection complexes were added onto the cells. The
ﬁnal concentration of antagomiR-155 and negative control was
80 nM. Alternatively, 6 h after applying the transfection reagent,
medium was replaced with fresh medium containing antibiotics
and 2% RS (for DLNC) or 5% FCS (for CD4+ T cells). The cells were
cultivated at 37 C, 5% CO2 for 20 h.
2.4. Reverse transcription—real time polymerase chain reaction
Total RNA was isolated using mi-Total RNA Isolation Kit
(Metabion, Martinsried, Germany). For analysis of miR-155 gene
expression each sample was split in two equal parts and reverse
transcribed using miR-155 Stem loop speciﬁc primer (Invitrogen,
Carlsbad, CA) or random hexamer primers (Fermentas, Vilnius,
Lithuania). The Stem loop primer for reaction of reverse
transcriptase was: 50-GTC GTA TCC AGT GCA GGG TCC GAG GTA
TTC GCA CTG GAT ACG ACC CCC TA-30. For analysis of cytokine
mRNA expression only random hexamer primers were used.
Reverse transcriptase was performed with MMLV (Moloney
Murine Leukemia Virus) reverse transcriptase (Fermentas),
according to the manufacturer’s instructions. Prepared cDNAs
were ampliﬁed by Maxima SYBR Green/ROX qPCR Master Mix
(Fermentas) according to the recommendations of the manufac-
turer in an ABI PRISM 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA). The PCR primers (Metabion) were as
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Fig. 1. miR-155 expression in lymph node cells. Lymph node cells were obtained from non-immunized rats (LNC) or from rats immunized with MBP7 days after the
immunization (DLNC). miR-155 expression was determined immediately after isolation of the cells (A) or DLNC were cultivated in the absence (medium) or presence of MBP
(10 mg/ml) for 24 h (B) before RNA isolation. Data from 5 (A) or 6 (B) rats per group are presented as mean +/ SD. *p < 0.05, statistical signiﬁcance between medium and MBP
culture.
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follows: b-actin forward primer 50-GCT TCT TTG CAG CTC CTTCGT-
30; b-actin reverse primer 50-CCA GCG CAG CGA TAT CG-30; miR-
155 forward primer 50-GGA GGT TAA TGC TAA TTG TGA TAG-30;
miR-155 reverse primer 50-GTG CAG GGT CCG AGG T-30; IFN-g
forward primer 50-TGG CAT AGA TGT GGA AGA AAA GAG-30; IFN-g
reverse primer 50-TGC AGG ATT TTC ATG TCA CCA T-30; IL-
17 forward primer 50-ATC AGG ACG CGC AAA CAT G-30; IL-
17 reverse primer 50-TGATCGCTGCTGCCTTCA C-30; IL-10 forward
primer 50-GAA GAC CCT CTG GAT ACA GCT GC-30; IL-10 reverse
primer 50-TGC TCC ACT GCC TTG CTT TT-30. Accumulation of PCR
products was detected in real time and the results were analysed
with 7500 System Software (AB). Relative RNA expression is
presented as 2dCt, where dCt is the difference between Ct values of
a gene of interest and the endogenous control (b-actin).
2.5. Statistical analysis
The results are presented as mean  SD of values obtained in
repeated experiments or in individual rats. A Student’s t test (two-
tailed) was performed for statistical analysis. A p value less than
0.05 was considered statistically signiﬁcant.
3. Results
3.1. miR-155 expression in DLNC of MBP-immunized rats
Expression of miR-155 was determined in lymph node cells of
non-immunized rats and in DLNC of rats immunized with MBP.
Although miR-155 expression was higher in DLNC, the difference
was without statistical signiﬁcance (Fig. 1A). DLNC were also re-
stimulated with MBP in vitro, and this antigen-speciﬁc re-
activation signiﬁcantly increased miR-155 expression in compari-
son to un-stimulated DLNC (Fig. 1B). The increase was also
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Fig. 2. miR-155 expression in lymph nodes and the CNS of the immunized rats.
DLNC and SCIC were isolated from MBP-immunized rats at day 7 or days 13–15 after
the immunization, respectively. RNA was isolated from the cells immediately after
the isolation (all cells) or CD4+ T cells were puriﬁed from DLNC and SCIC and RNA
was isolated immediately after the puriﬁcation. Data from 6 rats per group are
presented as mean +/ SD. *p < 0.05, statistical signiﬁcance between correspon-
dingDLNC and SCIC samples.#p < 0.05, statistical signiﬁcance between all cells and
CD4+ T cells.
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Fig. 3. Effects of miR-155 inhibition on cytokine expression in DLNC. DLNC were isolated from MBP-immunized rats 7 days after the immunization. DLNC were transfected
with antagomiR-155 or with negative control and they were stimulated with MBP. RNA was isolated after 20 h of incubation and cytokine mRNA expression was determined
by RT-PCR. Data from 5 independent experiments are presented as mean +/ SD. *p < 0.05, statistical signiﬁcance between antagomiR-155 and negative control.
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signiﬁcantly higher in comparison to lymph node cells obtained
from non-immunized rats.
3.2. miR-155 expression in CD4+ T cells isolated from DLNC and SCIC
CD4+ T cells were puriﬁed from DLNC isolated at the inductive
phase of EAE and from SCIC isolated at the peak of EAE.
miR-155 expression was determined in DLNC, SCIC and in the
puriﬁed CD4+ T cells. While miR-155 expression was signiﬁcantly
higher in DLNC than in SCIC, it was signiﬁcantly lower in CD4+ T
cells puriﬁed from DLNC in comparison to CD4+ T cells puriﬁed
from SCIC (Fig. 2). Also, CD4+ T cells isolated from SCIC had
signiﬁcantly higher expression of miR-155 than the whole SCIC
population.
3.3. Inhibition of miR-155 activity reduces IFN-g and IL-17 expression
in DLNC
miR-155 activity was inhibited in DLNC and CD4+ Tcells puriﬁed
from DLNC by a speciﬁc antagomiR-155. DLNC were re-stimulated
in vitro with MBP and CD4+ T cells with a cocktail of anti-CD3 and
anti-CD28 antibodies. Importantly, mRNA expression of IFN-g IL-
17 and IL-4, but not of tumour necrosis factor (TNF), IL-10 and
transforming growth factor (TGF)-b was signiﬁcantly lower in the
cultures treated with antagomiR-155 in comparison to those
treated with irrelevant (negative control) oligonucleotide, both in
DLNC (Fig. 3) and in CD4+ T cells (Fig. 4).
4. Discussion
Despite numerous studies, etiopathogenesis of multiple scle-
rosis is still not completely understood. Also, there is a necessity for
the highly efﬁcient therapeutics for the treatment of the disease.
Accordingly, further molecular dissection of the disease pathogen-
esis and identiﬁcation of novel therapeutic targets are needed.
Along the line, this study on the role of miR-155 in re-activation of
encephalitogenic T cells has been performed. Results presented
here suggest that miR-155 contributes to this essential process in
the disease pathogenesis.
miR-155 is expressed in various immune cells, including T and B
lymphocytes, dendritic cells and macrophages [4]. This miR is
involved in process of myelopoiesis, as well as in functional
regulation of myelopoietic cells. Importantly, miR-155 is important
in skewing Th cells towards Th1 and Th17 phenotype and
inhibiting Th2 differentiation [4,9,11]. Also, miR-155 stimulates
inﬂammatory activity of microglia, while it inhibits anti-inﬂam-
matory functions of astrocytes [7,8]. All of these data clearly imply
that miR-155 is a pro-inﬂammatory regulator in the immune
response. However, it has also been demonstrated that miR-155 is
very important for regulatory T cell differentiation. Its expression is
induced by a major regulatory T cell transcription factor –
FoxP3 and mir-155 deﬁcient animals have reduced numbers of
regulatory T cells. Although it seems that miR-155 deﬁciency
affects regulatory T cell ﬁtness, it does not seem to have any effect
on their functionality [9].
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Fig. 4. Effects of miR-155 inhibition on cytokine expression in DLNC. CD4+ T cells were puriﬁed from DLNC that were isolated from MBP-immunized rats 7 days after the
immunization and. CD4+ T cells were transfected with antagomiR-155 or with negative control and they were stimulated with anti-CD3+anti-CD28 antibody. RNA was
isolated after 20 h of incubation and cytokine mRNA expression was determined by RT-PCR. Data from 5 independent experiments are presented as mean +/ SD. *p < 0.05,
statistical signiﬁcance between antagomiR-155 and negative control.
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It has been shown previously that mir-155 deﬁcient mice are
highly resistant to EAE [10]. Differentiation of auto-reactive
Th1 and Th17 cells is impeded in miR-155 knockouts [12].
Moreover, dendritic cell activity needed for the development of
the effector Th cell subsets is impaired in these mice. Also, it has
recently been demonstrated that MOG35-55-speciﬁc, miR-155 de-
ﬁcient Th17 cells are inefﬁcient in inducing adoptive EAE in mice
[11]. Low expression of IL-23R seems to be important for the
inefﬁciency of the cells. These two studies clearly demonstrate that
miR-155 is very important for EAE pathogenesis. However, we have
to be cautious with interpretation of the results obtained with
knockout mice in EAE, as in such animals “one may expect many
diverse changes in several physiological processes, and one might
ﬁnd that after all is done, that another gene and its product can
replace the function of the gene that was disrupted” [13]. Although
originally this statement is on cytokine knockouts, the same could
be applicable to miR deﬁcient animals, as well. Also, knockout mice
used in the studies of EAE were made through deletion of B cell
integration cluster (BIC) from which primary transcript for miR-
155 is produced [14]. Although functional products of BIC
transcription other than miR-155 have not been identiﬁed so far,
there is a possibility that the used knockouts had some other
deﬁciencies besides miR-155-related ones. Thus, our study, in
which wild type animals were used and miR-155 was inhibited by
an antagomir during the limited period, eliminates the possibilities
of functional replacement and un-speciﬁc interference. Also, our
results were obtained in rats, thus excluding an option that the
effects of miR-155 function in CNS inﬂammatory disorders are
species-speciﬁc. Finally, and the most importantly, the studies in
mice did not investigate the role of miR-155 in the process of
encephalitogenic T cell re-activation. In our study, it is shown that
both in vitro and in vivo antigen-speciﬁc re-stimulation increases
miR-155 expression in encephalitogenic T cells. Also, it is
demonstrated that inhibition of miR-155 during the process of
re-stimulation leads to impaired effector functions of encephali-
togenic Th1 and Th17 cells, i.e., reduced expression of IFN-g and IL-
17. Interestingly, the major Th2 effector cytokine IL-4 expression
was also reduced under the inhibition of miR-155. Accordingly, it
was previously shown that a miR-155 inhibitor decreased secretion
of IL-4 in human peripheral blood mononuclear cells [15].
However, it has to be noted that IL-4 mRNA expression was
extremely low in DLNC and CD4+ T cells in our experiments. Thus, it
is reasonable to argue that our system is not adequate for general
comprehension of the miR-155-IL-4 interaction. Importantly,
expression of TNF, as well as of anti-inﬂammatory IL-10 and
TGF-b were not affected by the inhibition of miR-155 activity. This
fact clearly implied that the effect of miR-155 inhibition on
cytokine expression in encephalitogenic T cells was not general,
but rather speciﬁc. Of particular interest for a potential therapeutic
application of miR-155 inhibition is lack of its effects on IL-10 and
TGF-b as these are the major cytokines that prevent and reduce
excessive inﬂammatory T cell reactivity [16].
In conclusion, we show that miR-155 inhibition reduces major
Th1 and Th17 effector cytokine generation during the process of re-
stimulation of encephalitogenic cells. Having in mind the
importance of re-activation of encephalitogenic Th cells for the
pathogenesis of inﬂammatory CNS disorders [2,3], the observed
involvement of miR-155 in the process supports an idea to utilize
miR-155 targeting as a therapeutic approach in multiple sclerosis.
This idea is based on the facts that miR-155 level is elevated both in
peripheral blood mononuclear cells and in active brain lesions of
multiple sclerosis patients [6,7]. Still, the idea has to be further
tested in pre-clinical settings, especially in light of the observed
effects of miR-155 in regulatory T cells [9]. Thus, although a
signiﬁcant knowledge has been accumulated on the role of miR-
155 in multiple sclerosis pathogenesis, further research on the
topic is warranted.
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